Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

128 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Eltrombopag increases the hematopoietic supporting ability of mesenchymal stem/stromal cells.
Muntión S, Preciado S, Sánchez-Luis E, Corchete L, Díez-Campelo M, Osugui L, Martí-Chillón GJ, Vidriales MB, Navarro-Bailón A, De Las Rivas J, Sánchez-Guijo F. Muntión S, et al. Ther Adv Hematol. 2022 Dec 26;13:20406207221142137. doi: 10.1177/20406207221142137. eCollection 2022. Ther Adv Hematol. 2022. PMID: 36601635 Free PMC article.
Considering Bone Marrow Blasts From Nonerythroid Cellularity Improves the Prognostic Evaluation of Myelodysplastic Syndromes.
Arenillas L, Calvo X, Luño E, Senent L, Alonso E, Ramos F, Ardanaz MT, Pedro C, Tormo M, Marco V, Montoro J, Díez-Campelo M, Brunet S, Arrizabalaga B, Xicoy B, Andreu R, Bonanad S, Jerez A, Nomdedeu B, Ferrer A, Sanz GF, Florensa L. Arenillas L, et al. J Clin Oncol. 2016 Sep 20;34(27):3284-92. doi: 10.1200/JCO.2016.66.9705. Epub 2016 Jul 5. J Clin Oncol. 2016. PMID: 27382099
Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome.
Hoeks M, Bagguley T, van Marrewijk C, Smith A, Bowen D, Culligan D, Kolade S, Symeonidis A, Garelius H, Spanoudakis M, Langemeijer S, Roelofs R, Wiegerinck E, Tatic A, Killick S, Panagiotidis P, Stanca O, Hellström-Lindberg E, Cermak J, van der Klauw M, Wouters H, van Kraaij M, Blijlevens N, Swinkels DW, de Witte T; EUMDS Registry Participants. Hoeks M, et al. Leukemia. 2021 Jun;35(6):1745-1750. doi: 10.1038/s41375-020-01022-2. Epub 2020 Sep 18. Leukemia. 2021. PMID: 32948844 Free PMC article. No abstract available.
Neutrophil and platelet increases with luspatercept in lower-risk MDS: secondary endpoints from the MEDALIST trial.
Garcia-Manero G, Mufti GJ, Fenaux P, Buckstein R, Santini V, Díez-Campelo M, Finelli C, Ilhan O, Sekeres MA, Zeidan AM, Ito R, Zhang J, Rampersad A, Sinsimer D, Backstrom JT, Platzbecker U, Komrokji RS. Garcia-Manero G, et al. Blood. 2022 Jan 27;139(4):624-629. doi: 10.1182/blood.2021012589. Blood. 2022. PMID: 34758066 Free PMC article. Clinical Trial. No abstract available.
Machine Learning Improves Risk Stratification in Myelodysplastic Neoplasms: An Analysis of the Spanish Group of Myelodysplastic Syndromes.
Mosquera Orgueira A, Perez Encinas MM, Diaz Varela NA, Mora E, Díaz-Beyá M, Montoro MJ, Pomares H, Ramos F, Tormo M, Jerez A, Nomdedeu JF, De Miguel Sanchez C, Leonor A, Cárcel P, Cedena Romero MT, Xicoy B, Rivero E, Del Orbe Barreto RA, Diez-Campelo M, Benlloch LE, Crucitti D, Valcárcel D. Mosquera Orgueira A, et al. Hemasphere. 2023 Oct 11;7(10):e961. doi: 10.1097/HS9.0000000000000961. eCollection 2023 Oct. Hemasphere. 2023. PMID: 37841754 Free PMC article.
Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia.
Xicoy B, Germing U, Jimenez MJ, Garcia O, Garcia R, Schemenau J, Pedro C, Luño E, Bernal T, González B, Strupp C, Ardanaz M, Kuendgen A, Cedena MT, Neukirchen J, Calabuig M, Brunet S, Medina A, Amigo ML, Ramos F, Callejas M, Díez-Campelo M, Bailén A, Collado R, Vicente A, Arnan M, Valcarcel D, Arilla MJ, Zamora L, Benlloch L, Sanz G. Xicoy B, et al. Eur J Haematol. 2016 Jul;97(1):33-8. doi: 10.1111/ejh.12679. Epub 2015 Oct 22. Eur J Haematol. 2016. PMID: 26341961
Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations.
Martín I, Villamón E, Abellán R, Calasanz MJ, Irigoyen A, Sanz G, Such E, Mora E, Gutiérrez M, Collado R, García-Serra R, Vara M, Blanco ML, Oiartzabal I, Álvarez S, Bernal T, Granada I, Xicoy B, Jerez A, Calabuig M, Diez R, Gil Á, Díez-Campelo M, Solano C, Tormo M; Spanish Group of Myelodysplastic Syndromes (GESMD). Martín I, et al. Br J Haematol. 2021 Aug;194(4):708-717. doi: 10.1111/bjh.17675. Epub 2021 Jul 22. Br J Haematol. 2021. PMID: 34296432
Transfusion dependence development and disease evolution in patients with MDS and del(5q) and without transfusion needs at diagnosis.
Rojas SM, Díez-Campelo M, Luño E, Cabrero M, Pedro C, Calabuig M, Nomdedeu B, Cedena T, Arrizabalaga B, García M, Cerveró C, Collado R, Azaceta G, Ardanaz MT, Muñoz JA, Xicoy B, Rodríguez MJ, Bargay J, Morell MJ, Simiele A, del Cañizo C. Rojas SM, et al. Leuk Res. 2014 Mar;38(3):304-9. doi: 10.1016/j.leukres.2013.11.005. Epub 2013 Nov 15. Leuk Res. 2014. PMID: 24333115
Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS.
Kuendgen A, Nomdedeu M, Tuechler H, Garcia-Manero G, Komrokji RS, Sekeres MA, Della Porta MG, Cazzola M, DeZern AE, Roboz GJ, Steensma DP, Van de Loosdrecht AA, Schlenk RF, Grau J, Calvo X, Blum S, Pereira A, Valent P, Costa D, Giagounidis A, Xicoy B, Döhner H, Platzbecker U, Pedro C, Lübbert M, Oiartzabal I, Díez-Campelo M, Cedena MT, Machherndl-Spandl S, López-Pavía M, Baldus CD, Martinez-de-Sola M, Stauder R, Merchan B, List A, Ganster C, Schroeder T, Voso MT, Pfeilstöcker M, Sill H, Hildebrandt B, Esteve J, Nomdedeu B, Cobo F, Haas R, Sole F, Germing U, Greenberg PL, Haase D, Sanz G. Kuendgen A, et al. Leukemia. 2021 Mar;35(3):835-849. doi: 10.1038/s41375-020-0917-7. Epub 2020 Jun 29. Leukemia. 2021. PMID: 32595214 Free PMC article.
Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: a rationale for its inclusion into future classifications of myelodysplastic syndromes.
Calvo X, Arenillas L, Luño E, Senent L, Arnan M, Ramos F, Ardanaz MT, Pedro C, Tormo M, Montoro J, Díez-Campelo M, Arrizabalaga B, Xicoy B, Bonanad S, Jerez A, Nomdedeu B, Ferrer A, Sanz GF, Florensa L. Calvo X, et al. Mod Pathol. 2016 Dec;29(12):1541-1551. doi: 10.1038/modpathol.2016.146. Epub 2016 Aug 26. Mod Pathol. 2016. PMID: 27562492 Free article.
128 results